Similar articles

• ACP Journal Club. HPV-16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia ≥ grade 3 in young women.

  Budenholzer B. Budenholzer B. Ann Intern Med. 2012 Jul 17;157(2):JC2-6, JC2-7. doi: 10.7326/0003-4819-157-2-201207170-02007. Ann Intern Med. 2012. PMID: 22801705 No abstract available.
• Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.

  Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Arbyn M, et al. Vaccine. 2006 Aug 31;24 Suppl 3:S3/78-89. doi: 10.1016/j.vaccine.2006.05.117. Vaccine. 2006. PMID: 16950021 Review.
• Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.

  Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, Hatch K, Noller KL, Roach N, Runowicz C, Saslow D. Wright TC Jr, et al. Obstet Gynecol. 2004 Feb;103(2):304-9. doi: 10.1097/01.AOG.0000109426.82624.f8. Obstet Gynecol. 2004. PMID: 14754700 Review.
• Risk factors for cervical neoplasia in Denmark.

  Kjaer SK. Kjaer SK. APMIS Suppl. 1998;80:1-41. APMIS Suppl. 1998. PMID: 9693662
• A study of the impact of adding HPV types to cervical cancer screening and triage tests.

  Schiffman M, Khan MJ, Solomon D, Herrero R, Wacholder S, Hildesheim A, Rodriguez AC, Bratti MC, Wheeler CM, Burk RD; PEG Group; ALTS Group. Schiffman M, et al. J Natl Cancer Inst. 2005 Jan 19;97(2):147-50. doi: 10.1093/jnci/dji014. J Natl Cancer Inst. 2005. PMID: 15657345